Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
12.09
+0.59 (5.13%)
At close: Jan 22, 2026, 4:00 PM EST
12.09
0.00 (0.00%)
After-hours: Jan 22, 2026, 6:30 PM EST
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $231.10M in the quarter ending September 30, 2025, a decrease of -21.34%. This brings the company's revenue in the last twelve months to $788.90M, down -29.91% year-over-year. In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%.
Revenue (ttm)
$788.90M
Revenue Growth
-29.91%
P/S Ratio
0.83
Revenue / Employee
$876,556
Employees
900
Market Cap
634.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
| Dec 31, 2018 | 782.40M | 221.50M | 39.49% |
| Dec 31, 2017 | 560.90M | 72.10M | 14.75% |
| Dec 31, 2016 | 488.80M | -531.00K | -0.11% |
| Dec 31, 2015 | 489.33M | 84.87M | 20.98% |
| Dec 31, 2014 | 404.47M | 91.72M | 29.33% |
| Dec 31, 2013 | 312.75M | 30.86M | 10.95% |
| Dec 31, 2012 | 281.89M | 8.50M | 3.11% |
| Dec 31, 2011 | 273.38M | -12.79M | -4.47% |
| Dec 31, 2010 | 286.17M | 51.39M | 21.89% |
| Dec 31, 2009 | 234.79M | 56.23M | 31.49% |
| Dec 31, 2008 | 178.55M | -4.36M | -2.38% |
| Dec 31, 2007 | 182.92M | 30.18M | 19.76% |
| Dec 31, 2006 | 152.73M | 22.04M | 16.87% |
| Dec 31, 2005 | 130.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pacira BioSciences | 716.79M |
| Organogenesis Holdings | 465.22M |
| Ironwood Pharmaceuticals | 338.99M |
| Esperion Therapeutics | 303.80M |
| Canopy Growth | 200.02M |
| Kamada | 174.79M |
| SIGA Technologies | 172.25M |
| Eton Pharmaceuticals | 70.32M |
EBS News
- 7 days ago - NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading - WSJ
- 7 days ago - Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation - GlobeNewsWire
- 14 days ago - Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026 - GlobeNewsWire
- 14 days ago - Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa - GlobeNewsWire
- 15 days ago - Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site - GlobeNewsWire
- 2 months ago - Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access - GlobeNewsWire